Breakthrough Platform Trial for PCAS
Key facts
- Who runs it
- Kagawa University
- Where
- Japan12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 630 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 30 Jun 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Head Positioning
- Temperature Control
- Record updated
- 17 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Master Platform Eligibility:
- Adult patients aged 18 years or older
- Return of spontaneous circulation after cardiac arrest
- Persistent coma after return of spontaneous circulation (GCS motor score <6)
- Requirement for intensive care management; Head Positioning Domain Eligibility:
- Non-traumatic out-of-hospital or in-hospital cardiac arrest
- Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable); Temperature Control Domain Eligibility:
- Initial non-shockable cardiac arrest rhythm
- Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable)
- Ability to initiate temperature control therapy within 240 minutes after return of spontaneous circulation
Who cannot take part
- Cardiac arrest due to intracranial hemorrhage, subarachnoid hemorrhage, cerebral infarction, acute aortic dissection, or terminal cancer (including suspected cases)
- Severe chronic obstructive pulmonary disease requiring home oxygen therapy
- Traumatic cardiac arrest
- Master Platform Exclusion:
- Refusal of intensive care management
- Extracorporeal cardiopulmonary resuscitation (ECPR)
- Pregnancy or possible pregnancy
- Poor pre-arrest neurological function (CPC 3-4) or poor overall functional status (OPC 3-4)
- Pre-existing do-not-attempt-resuscitation (DNAR) order
- Expected early death
- Inability to obtain consent from a legally acceptable representative or the participant
- Enrollment judged inappropriate by the investigator; Head Positioning Domain Exclusion:
- Body temperature <30°C on hospital arrival
- Refusal of consent for participation in the head positioning domain
- Enrollment judged inappropriate by the investigator
- Patients using Impella® (a percutaneous mechanical circulatory support catheter) at the time of ICU admission
- Patients using an intra-aortic balloon pump (IABP) at the time of ICU admission
- Patients for whom feedback-controlled device-based temperature management or fever prevention is not being performed and is not planned at the time of ICU admission; Temperature Control Domain Exclusion:
- rCAST <4.5
- rCAST ≥17.0
- Body temperature <30°C on hospital arrival
- Refusal of consent for participation in the temperature control domain
- Enrollment judged inappropriate by the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this platform clinical trial is to evaluate whether specific post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.
Read full original descriptionShow less
This multicenter cluster-randomized crossover platform trial (BPT-PCAS) evaluates post-cardiac arrest care strategies within a shared master protocol structure. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods and subsequently cross over to alternative strategies according to a predefined allocation schedule.
The platform is designed to accommodate multiple independent intervention domains, each evaluating a different post-cardiac arrest care strategy under shared eligibility criteria, infrastructure, data management systems, and follow-up procedures. Participants may be enrolled in one or more active intervention domains according to platform availability and eligibility.
Participants will receive the post-cardiac arrest care strategy assigned to their participating hospital during the study period while otherwise undergoing standard intensive care management according to local practice and study protocols.
Participants will be followed for neurological outcomes including modified Rankin Scale (mRS), mortality, and safety outcomes at hospital discharge, 30 days, and 90 days after hospital admission.
The 2 groups in the trial
- Head Positioning Strategy (near-supine vs head elevation)Treatment being tested
Participants receive institutionally assigned post-cardiac arrest head positioning strategies according to the cluster-randomized crossover platform protocol, including head elevation (30°-45°) or near-supine positioning (0°-10°).
Treatment: Head Positioning
- Temperature Control Strategy (hypothermia vs normothermia)Treatment being tested
Participants receive institutionally assigned post-cardiac arrest temperature control strategies according to the cluster-randomized crossover platform protocol, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C).
Treatment: Temperature Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Breakthrough Platform Trial for Post Cardiac Arrest Syndrome
- Record updated
- 17 August 2026